KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash & Current Investments: 2010-2024

Historic Cash & Current Investments for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $105.6 million.

  • Emergent BioSolutions' Cash & Current Investments rose 59.34% to $249.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $778.6 million, marking a year-over-year increase of 86.22%. This contributed to the annual value of $105.6 million for FY2024, which is 5.46% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Cash & Current Investments of $105.6 million as of FY2024, which was down 5.46% from $111.7 million recorded in FY2023.
  • Over the past 5 years, Emergent BioSolutions' Cash & Current Investments peaked at $642.6 million during FY2022, and registered a low of $105.6 million during FY2024.
  • In the last 3 years, Emergent BioSolutions' Cash & Current Investments had a median value of $111.7 million in 2023 and averaged $286.6 million.
  • Per our database at Business Quant, Emergent BioSolutions' Cash & Current Investments soared by 269.94% in 2020 and then plummeted by 82.62% in 2023.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Cash & Current Investments stood at $621.5 million in 2020, then fell by 7.27% to $576.3 million in 2021, then grew by 11.50% to $642.6 million in 2022, then crashed by 82.62% to $111.7 million in 2023, then dropped by 5.46% to $105.6 million in 2024.